The macrofilaricidal efficacy of repeated doses of ivermectin for the treatment of river blindness by Walker, M et al.
Clinical Infectious Diseases
 • CID 2017:XX (XX XXXX) • 1Efficacy of Multiple-Dose Ivermectin
Macrofilaricidal Efficacy of Repeated Doses of Ivermectin 
for the Treatment of River Blindness
Martin Walker,1,2 Sébastien D. S. Pion,3 Hanwei Fang,4 Jacques Gardon,5 Joseph Kamgno,6,7 Maria-Gloria Basáñez,2 and Michel Boussinesq3
1Department of Pathobiology and Population Sciences and London Centre for Neglected Tropical Disease Research, Royal Veterinary College, Hatfield, and 2Department of Infectious Disease 
Epidemiology and London Centre for Neglected Tropical Disease Research, Imperial College London, United Kingdom; 3UMI233-TransVIHMI, Institut de Recherche pour le Développement, INSERM 
U1175, University of Montpellier, France; 4Department of Microbiology and Molecular Medicine, University of Geneva Medical School, Switzerland; 5Hydrosciences Montpellier, Institut de 
Recherche pour le Développement, France; and 6Centre for Research on Filariasis and Other Tropical Diseases, and 7Faculty of Medicine and Biomedical Sciences University of Yaoundé I, Yaoundé, 
Cameroon.
Background. Mass drug administration (MDA) with ivermectin is the cornerstone of efforts to eliminate human onchocerciasis 
by 2020 or 2025. The feasibility of elimination crucially depends on the effects of multiple ivermectin doses on Onchocerca volvulus. 
A single ivermectin (standard) dose clears the skin-dwelling microfilarial progeny of adult worms (macrofilariae) and temporarily 
impedes the release of such progeny by female macrofilariae, but a macrofilaricidal effect has been deemed minimal. Multiple doses of 
ivermectin may cumulatively and permanently reduce the fertility and shorten the lifespan of adult females. However, rigorous quan-
tification of these effects necessitates interrogating longitudinal data on macrofilariae with suitably powerful analytical techniques.
Methods. Using a novel mathematical modeling approach, we analyzed, at an individual participant level, longitudinal data on 
viability and fertility of female worms from the single most comprehensive multiple-dose clinical trial of ivermectin, comparing 
3-monthly with annual treatments administered for 3 years in Cameroon.
Results. Multiple doses of ivermectin have a partial macrofilaricidal and a modest permanent sterilizing effect after 4 or more 
consecutive treatments, even at routine MDA doses (150 µg/kg) and frequencies (annual). The life expectancy of adult O. volvulus is 
reduced by approximately 50% and 70% after 3 years of annual or 3-monthly (quarterly) exposures to ivermectin.
Conclusions. Our quantification of macrofilaricidal and sterilizing effects of ivermectin should be incorporated into transmis-
sion models to inform onchocerciasis elimination efforts in Africa and residual foci in Latin America. It also provides a framework 
to assess macrofilaricidal candidate drugs currently under development.
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In 1987 Merck & Co. Inc. committed to donate ivermectin for as 
long as needed to control human onchocerciasis. Subsequently, 
more than 2 billion treatments have been distributed in 29 coun-
tries throughout sub-Saharan Africa and in 6 countries in Latin 
America (http://www.merck.com/about/featured-stories/mecti-
zan.html) by mass drug administration (MDA) programs. The 
Onchocerciasis Elimination Program for the Americas (OEPA) was 
launched in 1992 and the African Programme for Onchocerciasis 
Control (APOC) was launched in 1995 to coordinate these 
efforts, maintain high MDA coverage, and control onchocercia-
sis as a public health problem. Since release of the World Health 
Organization’s Roadmap on Neglected Tropical Diseases (NTDs) 
[1], the objective (in Africa) has been refocused toward elimination 
of the infection (OEPA aimed at elimination from the outset).
Barring the Amazonian onchocerciasis focus [2], elimination 
in Latin America is broadly on course [3]. In sub-Saharan Africa, 
where 99% of the infection cases occur, and notwithstanding 
some notable elimination successes [4–6], transmission is ongo-
ing in many communities despite more than 15–20 rounds of 
annual (or 6-monthly) ivermectin treatments [7–10]. Addressing 
the question of whether elimination in Africa is feasible using 
current intervention strategies is a key issue. Before its closure in 
December 2015, APOC released guidance on alternative treat-
ment strategies to accelerate progress toward elimination [11].
Mathematical modeling has demonstrated that the effec-
tiveness and cost effectiveness of ivermectin MDA and the 
timeframes for elimination crucially depend on the long-term 
antifilarial action of ivermectin [12]. Ivermectin rapidly clears 
the skin-dwelling microfilarial progeny of Onchocerca volvulus, 
which is the filarial nematode that causes onchocerciasis, and 
temporarily prevents the release of new microfilariae by female 
worms. The dynamics of these so-called microfilaricidal and 
temporary sterilizing effects are well understood following a sin-
gle standard ivermectin dose (150 μg/kg) [13]. However, because 
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adult worms are long lived, with a life span of approximately 10 
years [14], they are exposed to multiple ivermectin doses dur-
ing an MDA program. Therefore, quantification of cumulative 
antifilarial effects on repeatedly exposed worms is essential for 
understanding the long-term epidemiological impact of MDA.
To date, cumulative antifilarial effects have been documented in 
an indirect manner (estimating their magnitude by fitting mod-
els to microfilarial trends following several treatment rounds), 
yielding conflicting results [15, 16]. However, direct observations 
on adult worm viability and reproductive status have not been 
linked to models for the underlying population biology of O. vol-
vulus, a powerful approach that can translate clinical trial data into 
measures of drug efficacy [17]. Macrofilaricidal activity has been 
inferred from the smaller proportion of live worms extracted from 
participants given high-intensity regimens (frequency of more than 
twice per year; dose >150 μg/kg) compared to those given standard 
regimens [18] or not treated [19]. Similarly, fertility indicators from 
female O. volvulus exposed to high-intensity regimens are lower 
than those from females exposed to standard regimens, yet such 
indicators have not been translated into cumulative and potentially 
permanent effects of incremental exposures to ivermectin.
Here, we use our recently developed mathematical frame-
work [17] to analyze longitudinal data on the viability and 
fertility of female adult O. volvulus collected from participants 
of the single largest and most recent randomized control trial, 
which was conducted in an endemic area of Cameroon [18] (a 
summary of other smaller and older trials is provided in the 
Supplementary Materials, Supplementary Figures 1–4 and 
Supplementary Table 1). We estimate the macrofilaricidal and 
antifertility activity of multiple ivermectin doses given at stand-
ard (annual) and high (3-monthly) frequencies and relate our 
findings to observations from previous studies on the antifilarial 
activity of multiple ivermectin doses and other macrofilaricidal 
therapies. We consider how these effects should be incorporated 
into transmission models to support onchocerciasis control and 
elimination and discuss how our findings can be used to assess 
the performance of candidate macrofilaricidal drugs.
METHODS
Trial Design and Data Collection
The data were collected between 1994 and 1998 during a clinical trial 
undertaken in a hyperendemic onchocerciasis focus with no history 
of ivermectin distribution or vector control and located in the Mbam 
River Valley, Central Region, Cameroon. The trial design is repre-
sented schematically in Figure 1; details are given in Gardon et al [18]. 
Briefly, 657 consenting males (to avoid contraindications associated 
with ivermectin in pregnancy), aged 18 to 60 years and with at least 
2 palpable onchocercomas (subcutaneous nodules), were randomly 
assigned to 1 of 4 ivermectin treatment groups (Table 1). A single, 
randomly selected nodule was surgically excised from each partici-
pant on up to 3 occasions: prior to ivermectin treatment in May 1994; 
3 years after the first trial dose in August 1997; and in either June 1998 
or November 1998, 6 or 12 months after the last ivermectin treat-
ment (Figure 1, Table 1). Following guidelines provided by Gardon 
et al [18], female worms within excised nodules were histologically 
classified (see Supplementary Materials) as nonfertile, N: live, nonfer-
tile worms including potentially fertile females not currently insemi-
nated, producing oocytes which transform into unfertilized ova and 
then degenerate as well as empty, senescent worms no longer produc-
ing oocytes; fertile, F: inseminated or re-inseminated and producing 
embryos of any stage up to live microfilariae; and moribund or dead, 
D: with few or no internal organs, collapsed body wall, and partial or 
total calcification. Data were analyzed per protocol rather than intent-
to-treat; individuals who missed a treatment were systematically 
excluded from the cohort. We did not analyze data on male worms 
because their smaller size hinders their detection in histological sec-
tions and because very few were identified as dead or moribund [18]. 
This is common [20], probably because males tend to leave nodules 
to seek females [21] and may die outside of nodules.
Modeling Approach and Statistical Inference
We used the treatment submodel embedded within our trans-
mission model EPIONCHO [22, 23], originally developed to 
describe the population dynamics of adult female O. volvulus 
exposed to a single standard dose (150 μg/kg) of ivermectin 
[13]. We extended this model to track mean numbers of live 
and dead worms per host, in addition to the fertility (fertile 
or nonfertile) status of live worms, through different multi-
ple-dose ivermectin treatment regimens. It was assumed that 
the (prior) life expectancy of (untreated) adult female O. volvu-
lus was 10 years, with 95% of worms dead by age 14 years [14]. 
Mathematical details are given in the Supplementary Materials, 
a schematic in Supplementary Figure 5 and a list of parameter 
definitions in Supplementary Table 2.
Table 1. Summary of Trialed Ivermectin Treatment Regimens
Group Dose Frequency Descriptiona
1, Standard 150 µg/kg Annual 3 × 150 µg/kg annually for 3 years
2, High dose 400–800 µg/kg Annual 1 × 400 µg/kg and then 2 × 800 µg/kg for 2 years
3, High frequency 150 µg/kg 3-monthly 12 × 150 µg/kg 3-monthly for 3 years
4, High dose, high frequency 400–800 µg/kg 3-monthly 2 × 400 µg/kg and then 10 × 800 µg/kg for 2.5 years
aAll individuals were additionally treated with a clearing dose of 150 µg/kg 3 months prior to the start of the study (immediately after the baseline nodulectomy) and with a final dose of 
150 µg/kg 6 months after the final treatment.
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The framework captures macrofilaricidal and sterilizing 
(temporary and/or permanent) effects, referred to collec-
tively as antifilarial effects, on worms differentially exposed 
to ivermectin via parameters that increase the relevant pop-
ulation dynamics rates above that of unexposed worms (eg, 
an excess mortality rate; Supplementary Figure 6). These 
effects can vary with dose and frequency and can change 
dynamically such that the cumulative effects on viability or 
fertility can accrue in a constant decreasing or increasing 
manner with incremental exposures. Because of ongoing 
transmission, previously unexposed worms could have been 
acquired at any time during the trial. Therefore, we modeled 
explicitly the antifilarial effects on differentially exposed 
worms (Supplementary Figure 6) [13].
We modeled the temporally dynamic proportion of live female 
worms and the proportion of fertile (live) worms within hosts 
given each treatment regimen. By introducing host-specific ran-
dom effects, we reconciled the modeled group-based dynamics 
with participant-specific longitudinal data, producing a statisti-
cal model to account for correlation among worm counts made 
repeatedly on the same individual, permitting (random) nonspe-
cific variation among participants. We modeled state probabili-
ties (proportions of live and fertile worms) to nullify the effects of 
variation in the incidence of new infections among participants 
Figure 1. Schematic representation of the study design.
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(see Supplementary Materials for details). We did not use data 
on skin microfilarial densities [18] to avoid invoking additional 
assumptions on the production of microfilariae by female worms 
and on the competing dynamics of ivermectin’s microfilaricidal 
and sterilizing effects [13]. Hence, because the focus here is on 
antimacrofilarial activity, we used data on macrofilariae only.
We considered 4 models, model 0 to model 3, covering all com-
binations of antifilarial effects, with model 0 being the null model 
of no macrofilaricidal or permanent sterilizing activity of iver-
mectin but including a temporary sterilizing effect [13] (Table 2). 
We assumed that the first exposure to ivermectin does not exert 
any macrofilaricidal or permanent sterilizing effect [13], and we 
did not consider postulated prophylactic effects (Supplementary, 
Prophylactic effects of ivermectin). We fitted these models to the 
data in a Bayesian framework using Markov chain Monte Carlo 
techniques (see Supplementary Materials for details). We reflected 
a priori uncertainty in parameter values using prior distributions 
(priors). Parameters with information available in the literature 
were assigned informative priors, reflecting published uncer-
tainties. These include the parameters that define the temporary 
sterilizing effect of a single standard dose of ivermectin [13], per-
mitting permanent sterilizing effects to be resolved. Parameters 
without published information were assigned uninformative pri-
ors and include all parameters that govern the macrofilaricidal 
and permanent sterilizing activity (Supplementary Table 2).
Transmission Intensity
Without data on transmission intensity during the trial (eg, 
numbers of infective larvae per blackfly) [18], we tested the 
robustness of the models to different assumptions on short-
term (within year) and long-term (between year) changes in 
transmission. We fitted 4 variants (A to D) of models 0 to 3 
(Table 2) covering combinations of short-term seasonal var-
iation in transmission (mediated by fluctuations in the abun-
dance of blackflies) and a long-term decline in transmission, 
perhaps induced by the trial (although this was unlikely; see 
Supplementary Materials for discussion). To capture sea-
sonal variation, we fitted a sinusoidal function to data on 
blackfly numbers collected in the vicinity just before the trial 
(see Supplementary Materials for details). To capture long-
term reductions in transmission, we modeled an exponential 
decline such that during the last year of the trial, the intensity 
of transmission was approximately half of its initial value (see 
Supplementary Materials and Supplementary Figure 7).
RESULTS
Antifilarial Indications and Population Dynamics
The best fitting models under all assumptions of seasonal varia-
tion and long-term declines in transmission include both macro-
filaricidal activity and permanent sterilization (Supplementary 
Table 3), indicating that both processes operate. Model 3A had 
the lowest deviance information criterion (DIC) [24], indicat-
ing adequacy of a constant transmission assumption (Table 2). 
Parameter estimates are only modestly affected by different 
assumptions on seasonal variation and long-term declines in 
transmission (Figure 2; Supplementary Table 4).
Figure 3 shows the dynamics, estimated from model 3A, in the 
proportions of live and fertile female O. volvulus through the 4 
multiple-dose treatment regimens (Table 1). Model 3A includes 
macrofilaricidal activity, permanent sterilization, and constant 
(seasonal and long-term) transmission (parameter estimates 
are depicted in Supplementary Figure 8). Depicted are both the 
mean dynamics among all trial participants given a particu-
lar regimen and the individual (host) dynamics. The observed 
(grouped) data are shown for visual appraisal of model fit.
Macrofilaricidal Activity
The decline in the proportion of live worms (Figure 3A and 3B) 
is protracted and driven by the permanent excess (additional) 
mortality of live worms exposed to ivermectin compared to 
unexposed worms (Figure 2A). Macrofilaricidal activity is not 
significantly associated with dose (150 μg/kg vs 800 μg/kg; 
Figure 2B). The pace at which the macrofilaricidal effect accu-
mulates declines with incremental exposures (Figure 2C nega-
tive incremental exposure adjustment for all model variants).
Figure 4 shows how the estimated life expectancy of female O. 
volvulus is reduced with increasing exposure to ivermectin (see 
Table 2. Models and Variants Incorporating Different Antifilarial Effects and Different Assumptions on the Transmission Dynamics 
During the Trial
Model Permanent Antifilarial Activity Variant Assumptions on Short-term and Long-term Changes in Transmission
0 • No macrofilaricidal activity
• No sterilizing activity
A • Constant short-term transmission
• Constant long-term transmission
1 • No macrofilaricidal activity
• Sterilizing activity
B • Seasonal short-term transmission
• Constant long-term transmission
2 • Macrofilaricidal activity
• No sterilizing activity
C • Constant short-term transmission
• Declining long-term transmission
3 • Macrofilaricidal activity
• Sterilizing activity
D • Seasonal short-term transmission
• Declining long-term transmission
Nota bene: All variants A to D of models 0 to 3 were fitted to the data separately (ie, 16 separate fits in total).
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Supplementary Materials for details of this calculation). Worms 
that establish in participants before the first treatment with iver-
mectin (and therefore are maximally exposed) have a life expec-
tancy of approximately 4.8 years for the standard-dose annual 
regimen and 3.3 years for the 3-monthly regimen. This corre-
sponds to 50% and 67% reductions compared to hypothetically 
unexposed worms, which have an estimated life expectancy of 9.6 
years based on the life expectancy of O. volvulus in West African 
savannah [14].
Sterilizing Activity
The modeled transient effects of the temporary sterilizing effect 
(Supplementary Figure 6) drives the oscillating proportion of 
fertile (live) worms (Figure 3C and 3D). The more protracted 
systematic decline is caused predominantly by the permanent 
sterilization of worms that are exposed to ivermectin on multi-
ple occassions. Although this effect is estimated with substan-
tial uncertainty (Figure 2D, models that included a permanent 
sterilizing effect (Table 2) were superior (according to the DIC) 
to those that omitted it (Supplementary Table 3). There is no 
statistically significant effect of dose on permanent sterilization 
(Figure 2E), but there is a nonsignificant tendency for the higher 
dose regimens to elicit a stronger effect. The pace at which the 
permanent sterilizing effect accumulates remains constant with 
incremental exposures (Figure 2F).
DISCUSSION
Multiple doses of ivermectin have a partial macrofilaricidal 
effect and a modest permanent and irreversible sterilizing 
effect on female O. volvulus after 4 or more consecutive treat-
ments, even at the annual frequency and 150 μg/kg dose used 
for MDA. A high 800-μg/kg dose does not significantly mod-
ify either effect. We used the scaffold of our newly developed 
modeling framework [17], linking longitudinal data collected 
at different follow-up times to the effects of ivermectin on 
fundamental parasite population processes. This was done in 
order to estimate the pronounced macrofilaricidal effect of 
3 years of annual or 3-monthly multiple-dose regimens as, 
respectively, a 50% and 67% reduction in the life expectancy 
of female O. volvulus.
In their original analysis of these data, Gardon et al [18] 
identified a statistically significant higher proportion of dead 
female worms in patients who received the 3-monthly treat-
ment compared to those treated annually. Raised proportions 
of dead worms from treated compared to untreated controls 
were also reported from trials in Liberia, Guatemala, and Sierra 
Leone (see Supplementary Materials and Supplementary Table 
1 for a summary of these trials). The data in these studies were 
analyzed using traditional statistical techniques, making it 
impossible to translate proportions of dead worms (observed at 
variable follow-up times) into estimates of worm life expectancy. 
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Figure 2. Summary of estimated parameters that define the antifilarial activity of multiple doses of ivermectin under different assumptions on the transmission dynamics 
during the trial. In each panel, the data points and vertical lines indicate the means and 95% Bayesian credible intervals (BCIs) of the posterior distributions estimated from 
variants A (constant short-term and long-term transmission), B (seasonal short-term transmission; constant long-term transmission), C (constant short-term transmission; 
declining long-term transmission), and D (seasonal short-term transmission; declining long-term transmission) of the best fitting model 3 (see Supplementary Table 3 for 
deviance information criteria). The horizontal dotted lines in each panel indicate the null (zero) effect of each parameter. Hence, parameters with BCIs that cross the dotted 
line can be interpreted as not statistically significantly different from zero. For example, in panels (A) and (D) none of the BCIs include 0, indicating statistically significant 
(permanent) macrofilaricidal and sterilizing activity of multiple-dose ivermectin regimens. By contrast, in panels (B) and (E) all BCIs cross 0, indicating no statistically signifi-
cant effect of dose on either macrofilaricidal or permanent sterilizing activity. The parameter posteriors estimated from the model variants are generally similar and therefore 
robust to different assumptions on the transmission dynamics during the trial.
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Moreover, with the exception of 9 treated participants from a 
trial in Guatemala [25], (Supplementary Table 1), none of the 
previous trials followed participants longitudinally.
Similarly, the original conclusions on the sterilizing activity 
of the multiple-dose regimens were based on comparisons of 
proportions of fertile worms among differently treated partic-
ipants [18]. A lower proportion among 3-monthly compared 
to annually treated participants was reported; however, it was 
not possible to determine whether this was consistent with the 
(since well-described [13]) temporary sterilizing effect of iver-
mectin or indicative of irreversible impairment (a conundrum 
discussed elsewhere [26]). Our modeling approach resolves this 
and suggests a modest, permanent sterilization effect, albeit 
bounded by high uncertainty because both the macrofilaricidal 
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Figure 3. Dynamics of Onchocerca volvulus viability and fertility through multiple rounds of ivermectin treatment. Each panel depicts either the percentage of live female 
O. volvulus (panels A and B) or the percentage of fertile (live) female O. volvulus (panels C and D) exposed to ivermectin treatments given annually (panels A and C) or 
3-monthly (panels B and D) at standard (150 µg/kg) and high doses (800 µg/kg). The thick gray and black solid lines indicate, respectively, the marginal mean (averaged across 
all hosts) dynamics for standard or high-dose regimens. The thin gray lines indicate the individual host dynamics mediated by the estimated random effects terms within the 
statistical model (see Supplementary Materials for statistical details). For clarity, no graphical distinction is given among individual hosts given either standard or high-dose 
regimens. In each panel, the triangular and circular markers denote, respectively, the observed percentages of live or fertile (live) females extracted from participants given 
either standard or high-dose regimens. Vertical error bars denote 95% confidence intervals that were calculated using a nonparametric weighted bootstrapping procedure to 
account for the variable number of female O. volvulus extracted from each host. Horizontal error bars (often narrower than the data point) indicate the range of nodulectomy 
dates at each sampling round.
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and sterilizing effects influence observed proportions of fer-
tile worms. The macrofilaricidal activity of ivermectin kills an 
increasing proportion of nonfertile worms before they become 
fertile for the first time, altering the worm population structure 
to comprise relatively more juvenile worms.
We recently used our modeling framework to quantify the 
macrofilaricidal activity of doxycycline, a tetracycline antibiotic 
that depletes the endosymbiotic Wolbachia bacteria essential to 
O. volvulus viability and fertility [17]. We reported an 80% reduc-
tion in the life expectancy of O. volvulus treated with 4–6 weeks 
of 100 mg or 200 mg daily doxycycline, which is higher than the 
macrofilaricidal efficacy of multiple doses of ivermectin esti-
mated here. Other macrofilaricidal therapies include intravenous 
suramin, which is poorly tolerated with significant side effects 
and is therefore seldom used, and flubendazole, which was orig-
inally associated with serious intramuscular injection-site reac-
tions [27] and subsequent development of an oral reformulation 
has been recently discontinued over toxicology concerns [28]. 
Hence, doxycycline is the de facto gold standard macrofilaricidal 
treatment for onchocerciasis, despite possible challenges associ-
ated with adherence to a relatively long treatment course.
This paucity of macrofilaricides emphasizes the need for new 
drugs to improve treatment of onchocerciasis in clinical set-
tings and to bolster the armory of treatment options to assist 
with global control and elimination efforts. There is substantial 
and ongoing research into new drugs and drug combinations 
[29]. The analysis presented here, like that used to evaluate the 
efficacy of doxycycline, shows that the interpretation of clinical 
trial data is facilitated by population dynamics modeling tech-
niques. These approaches can be used in a retrospective, ana-
lytical manner (as presented here) and prospectively to inform 
clinical trial design and the formulation of so-called target 
product profiles by simulating (parasitological or other) out-
comes using postulated antifilarial activities.
The specific structure of the model used here is based 
on the treatment submodel embedded within EPIONCHO 
[22, 23], a transmission model that is used to explore the 
effectiveness of current and alternative intervention strat-
egies that target onchocerciasis elimination in Africa [23, 
30, 31]. In the future, to give our efficacy estimates more 
explicit programmatic interpretation, we will explore how 
partial macrofilaricidal and sterilizing effects of repeated 
rounds of ivermectin given during MDA alter current pro-
jections on the feasibility of achieving elimination targets 
[1, 32]. This will include revising projections on annual and 
6-monthly treatment [30] and modeling the potential ben-
efit of 3-monthly MDA regimens; the latter showing a sig-
nificantly higher macrofilaricidal efficacy than annual MDA. 
Irrespective of our new understanding of the partial macro-
filaricidal activity of repeated doses of ivermectin, maintain-
ing high coverage and adherence to treatment, particularly 
in highly endemic areas, will remain extremely important to 
the effectiveness of MDA [22, 30].
Some epidemiological projections that incorporate an instan-
taneous macrofilaricidal effect of ivermectin have been made 
using the ONCHOSIM transmission model [22, 33]. These anal-
yses attribute long-term reductions in microfilarial densities to 
either macrofilaricidal or permanent sterilizing activity, but not 
to both mechanisms acting simultaneously. Furthermore, their 
estimates of macrofilaricidal efficacy, based on clinical trial data 
from Guatemala [34] of 3-monthly treatments (Supplementary 
Table 1), rested on an assumption of no ongoing transmission 
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Figure 4. The life expectancy of adult Onchocerca volvulus multiply exposed to ivermectin. The dashed and dotted lines in panel A show the estimated life expectancy 
(in years) of adult female O. volvulus exposed to annual and 3-monthly treatments with ivermectin at a standard dose (150 µg/kg) (there is no substantive difference in the 
corresponding estimates for a high dose of 800 µg/kg dose, Figures 2 and 3). The solid line in this panel (A) depicts the estimated life expectancy of hypothetically unexposed 
worms. In panel (B), the dashed and dotted lines express the estimated life expectancies as percentage reductions compared to hypothetically unexposed worms. Estimates 
are plotted against the date of infection, that is, the time of establishment of female worms. Treatment dates with ivermectin are represented by the triangles: 3-monthly 
treatments on the top row and annual treatments below. Hence, worms that establish at an earlier date are exposed to more treatments and incur greater reductions in life 
expectancy. In each panel, gray shaded areas represent 95% Bayesian credible intervals. Life expectancies were calculated from the estimated parameter posteriors of model 
3A (the best fitting model, see Supplementary Table 3 for deviance information criteria). Details of these calculations are given in the Supplementary Materials.
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during the trial and no resorption of dead worms [17, 35], risk-
ing underestimation of the true macrofilaricidal effect. Our 
approach untangles the permanent sterilizing and macrofilari-
cidal effects for both annual and 3-monthly ivermectin regimens 
at different doses and adjusts for the diluting effects of ongoing 
transmission.
Notwithstanding the partial macrofilaricidal activity of iver-
mectin, the search for new drugs to assist with the control and 
elimination of onchocerciasis remains extremely important 
[29]. Ivermectin cannot be used safely in loiasis–onchocercia-
sis co-endemic areas of West and Central Africa because of the 
risk of severe adverse events associated with high-grade Loa 
loa microfilaremia [36, 37]. Many communities in these areas 
are currently not served with effective onchocerciasis control. 
In such areas, macrofilaricidal (and permanently sterilizing) 
anti-Wolbachia therapies that do not affect L. loa (devoid of 
Wolbachia) are particularly promising. Anti-Wolbachia ther-
apies may also impede parasite development in the blackfly 
vector [38], exerting a potential transmission-blocking effect. 
Elsewhere in Africa, reports of suboptimal responses to iver-
mectin continue [39] and should be considered an impetus 
to seeking alternative drugs to mitigate potentially emerging 
ivermectin resistance. Moxidectin is a promising candidate for 
MDA in these circumstances [40].
CONCLUSIONS
We modeled longitudinal data from the most comprehensive 
clinical trial of multiple doses of ivermectin treatment using 
a powerful and contemporary population dynamics and sta-
tistical framework. We show that 4 or more consecutive treat-
ments with ivermectin are partially macrofilaricidal and exert a 
permanent sterilizing effect on female O. volvulus, even at the 
standard dose and frequency used in routine MDA in Africa. It 
is essential to incorporate these effects into mathematical trans-
mission models to reevaluate existing projections on the feasi-
bility of eliminating onchocerciasis.
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